Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Incorporating Immune Checkpoint Inhibitors Into Practice for Advanced Urothelial Cancer: Expert Perspectives From Italy

Listen to Guiseppe Procopio, MD, and Cora N. Sternberg, MD, FACP, discuss in Italian the latest clinical data on immune checkpoint inhibitors for advanced urothelial cancer.
person default
Giuseppe Procopio, MD
Cora N. Sternberg, MD, FACP
Released: February 4, 2021

In this episode, Guiseppe Procopio, MD, and Cora N. Sternberg, MD, FACP, discuss in Italian the latest immuno-oncology developments in the treatment of urothelial cancer.

Presenters:

Guiseppe Procopio, MD  
Head of the Medical Oncology Genitourinary, Istituto Nazionale Tumori
Medical Oncology
Fondazione IRCCS Istituto Nazionale dei Tumori
Milan, Italy

Cora N. Sternberg, MD, FACP
Professor of Medicine
Department of Hematology/Oncology
Weill Cornell Medicine
New York, New York, USA

Acknowledgements

Supported by an educational grant from
Pfizer, Inc. and EMD Serono

Related Content

First results from PEACE-1 trial of abiraterone with or without local radiotherapy plus SOC in metastatic CSPC, from ASCO 2021 as reported by Clinical Care Options (CCO)

Released: June 17, 2021

Downloadable slideset from Eric Jonasch, MD on managing irAEs in patients with advanced RCC, from Clinical Care Options (CCO).

Eric Jonasch, MD Released: June 16, 2021

Downloadable slideset from Dr Elizabeth R. Plimack on first-line treatment options for patients with RCC, from Clinical Care Options (CCO)

Elizabeth R. Plimack, MD, MS Released: June 16, 2021

Downloadable slideset from Neeraj Agarwal, MD on treatment options for salvage therapy in advanced RCC, from Clinical Care Options (CCO)

Neeraj Agarwal, MD Released: June 16, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue